Seize the rise of vaccine stocks: I think the two major vaccine stocks you can't miss

As empathy spread, vaccine stocks became the focus of investors' attention. Among the many vaccine stocks, I think the two stocks with the highest returns are CureVac and NovaVax, respectively. Both companies' stock prices reached three digits during the peak of empathy, showing strong market performance and investment potential.

First place: CureVac
$CureVac(CVAC.US)$
CureVac is a German biotechnology company focused on the development and commercialization of mRNA vaccines. Its innovative mRNA technology has been widely recognized and applied around the world. At the peak of empathy, CureVac's stock price broke through three digits, showing its huge market potential and investment value. Given its continued investment in R&D and the expansion of the global market, I believe CureVac has great potential for future growth.

Second place: Novavax
$Novavax(NVAX.US)$
Novavax is an American biotech company focused on developing innovative vaccines. Its vaccine technology based on recombinant proteins has been used significantly during the COVID-19 pandemic. Novavax's vaccine has been approved and promoted in many countries and regions around the world, so that its stock price also reached three digits during the peak of empathy. As the company continues to expand its product line and market, I am confident Novavax will continue to provide significant returns to investors.

Personal investment analysis
I am optimistic about the future performance of CureVac and NovaVax, and have purchased 1000 shares of CureVac as a small investment. I believe these two stocks will provide investors with significant returns as global demand for vaccines continues to grow. With their leading technology and market position, CureVac and Novavax are bound to occupy an important position in the future biopharmaceutical market.

All in all, CureVac and Novavax are the most promising vaccine stocks in the current market and are worthy of investors' attention and investment. At the peak of empathy, the performance of these two stocks proved their strong market competitiveness and growth potential. For investors looking for high returns in the vaccine sector, CureVac and NovaVax are certainly the best choices.